<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:18:29Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9835564" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9835564</identifier>
        <datestamp>2023-01-18</datestamp>
        <setSpec>acel</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="acel13754" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Aging Cell</journal-id>
              <journal-id journal-id-type="iso-abbrev">Aging Cell</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1474-9726</journal-id>
              <journal-id journal-id-type="publisher-id">ACEL</journal-id>
              <journal-title-group>
                <journal-title>Aging Cell</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1474-9718</issn>
              <issn pub-type="epub">1474-9726</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9835564</article-id>
              <article-id pub-id-type="pmcid">PMC9835564</article-id>
              <article-id pub-id-type="pmc-uid">9835564</article-id>
              <article-id pub-id-type="pmid">36515353</article-id>
              <article-id pub-id-type="pmid">36515353</article-id>
              <article-id pub-id-type="doi">10.1111/acel.13754</article-id>
              <article-id pub-id-type="publisher-id">ACEL13754</article-id>
              <article-id pub-id-type="other">ACE-22-0614-SC.R1</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Short Communication</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Short Communications</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Oral nicotinamide riboside raises <styled-content style="fixed-case" toggle="no">NAD</styled-content>+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin</article-title>
                <alt-title alt-title-type="left-running-head">Vreones et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="acel13754-cr-0001" contrib-type="author">
                  <name>
                    <surname>Vreones</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref rid="acel13754-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acel13754-cr-0002" contrib-type="author">
                  <name>
                    <surname>Mustapic</surname>
                    <given-names>Maja</given-names>
                  </name>
                  <xref rid="acel13754-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acel13754-cr-0003" contrib-type="author">
                  <name>
                    <surname>Moaddel</surname>
                    <given-names>Ruin</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6812-0127</contrib-id>
                  <xref rid="acel13754-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acel13754-cr-0004" contrib-type="author">
                  <name>
                    <surname>Pucha</surname>
                    <given-names>Krishna A.</given-names>
                  </name>
                  <xref rid="acel13754-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acel13754-cr-0005" contrib-type="author">
                  <name>
                    <surname>Lovett</surname>
                    <given-names>Jacqueline</given-names>
                  </name>
                  <xref rid="acel13754-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acel13754-cr-0006" contrib-type="author">
                  <name>
                    <surname>Seals</surname>
                    <given-names>Douglas R.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2391-9824</contrib-id>
                  <xref rid="acel13754-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acel13754-cr-0007" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Kapogiannis</surname>
                    <given-names>Dimitrios</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2181-3118</contrib-id>
                  <xref rid="acel13754-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>kapogiannisd@mail.nih.gov</email>
                  </address>
                </contrib>
                <contrib id="acel13754-cr-0008" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Martens</surname>
                    <given-names>Christopher R.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0578-2948</contrib-id>
                  <xref rid="acel13754-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <address>
                    <email>cmartens@udel.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="acel13754-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Human Neuroscience Section</named-content>
                <institution>National Institute on Aging</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="acel13754-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Integrative Physiology</named-content>
                <institution>University of Colorado Boulder</institution>
                <city>Boulder</city>
                <named-content content-type="country-part">Colorado</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="acel13754-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Kinesiology &amp; Applied Physiology</named-content>
                <institution>University of Delaware</institution>
                <city>Newark</city>
                <named-content content-type="country-part">Delaware</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Dimitrios Kapogiannis, Chief, Human Neuroscience Section, National Institute on Aging (NIA/NIH), 3001 S. Hanover St, 5 floor – NIA, Baltimore, MD 21225, USA.<break/>
Email: <email>kapogiannisd@mail.nih.gov</email>
<break/>
Christopher R. Martens, Department of Kinesiology &amp; Applied Physiology, University of Delaware, 540 S College Ave, Newark, DE 19713, USA.<break/>
Email: <email>cmartens@udel.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <volume>22</volume>
              <issue seq="130">1</issue>
              <issue-id pub-id-type="doi">10.1111/acel.v22.1</issue-id>
              <elocation-id>e13754</elocation-id>
              <history>
                <date date-type="rev-recd">
                  <day>08</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>23</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>28</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2023 The Anatomical Society and John Wiley & Sons Ltd-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Aging Cell</italic> published by Anatomical Society and John Wiley &amp; Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:ACEL-22-e13754.pdf"/>
              <abstract>
                <title>Abstract</title>
                <p>Declining nicotinamide adenine dinucleotide (NAD<sup>+</sup>) concentration in the brain during aging contributes to metabolic and cellular dysfunction and is implicated in the pathogenesis of aging‐associated neurological disorders. Experimental therapies aimed at boosting brain NAD<sup>+</sup> levels normalize several neurodegenerative phenotypes in animal models, motivating their clinical translation. Dietary intake of NAD<sup>+</sup> precursors, such as nicotinamide riboside (NR), is a safe and effective avenue for augmenting NAD<sup>+</sup> levels in peripheral tissues in humans, yet evidence supporting their ability to raise NAD<sup>+</sup> levels in the brain or engage neurodegenerative disease pathways is lacking. Here, we studied biomarkers in plasma extracellular vesicles enriched for neuronal origin (NEVs) from 22 healthy older adults who participated in a randomized, placebo‐controlled crossover trial (NCT02921659) of oral NR supplementation (500 mg, 2x /day, 6 weeks). We demonstrate that oral NR supplementation increases NAD<sup>+</sup> levels in NEVs and decreases NEV levels of Aβ42, pJNK, and pERK1/2 (kinases involved in insulin resistance and neuroinflammatory pathways). In addition, changes in NAD(H) correlated with changes in canonical insulin–Akt signaling proteins and changes in pERK1/2 and pJNK. These findings support the ability of orally administered NR to augment neuronal NAD<sup>+</sup> levels and modify biomarkers related to neurodegenerative pathology in humans. Furthermore, NEVs offer a new blood‐based window into monitoring the physiologic response of NR in the brain.</p>
              </abstract>
              <abstract abstract-type="graphical">
                <p>Oral nicotinamide riboside (NR) supplementation increased nicotinamide adenine dinucleotide (NAD+) in extracellular vesicles enriched for neuronal origin (NEVs) and decreased biomarkers of neurodegenerative disease and insulin signaling in late middle‐aged and older adults.<boxed-text position="anchor" content-type="graphic" id="acel13754-blkfxd-0001"><graphic xlink:href="ACEL-22-e13754-g003.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p>
              </abstract>
              <kwd-group>
                <kwd id="acel13754-kwd-0001">extracellular vesicles</kwd>
                <kwd id="acel13754-kwd-0002">NAD<sup>+</sup>
</kwd>
                <kwd id="acel13754-kwd-0003">NADH</kwd>
                <kwd id="acel13754-kwd-0004">neurodegenerative disease</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>American Federation for Aging Research
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000965</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institute on Aging
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000049</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K01 AG054731</award-id>
                  <award-id>T32 AG000279</award-id>
                  <award-id>UL1 TR001082</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="0"/>
                <page-count count="7"/>
                <word-count count="4087"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:12.01.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="ACEL13754-cit-2001"><string-name><surname>Vreones</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mustapic</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Moaddel</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Pucha</surname>, <given-names>K. A.</given-names></string-name>, <string-name><surname>Lovett</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Seals</surname>, <given-names>D. R.</given-names></string-name>, <string-name><surname>Kapogiannis</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Martens</surname>, <given-names>C. R.</given-names></string-name> (<year>2023</year>). <article-title>Oral nicotinamide riboside raises <styled-content style="fixed-case" toggle="no">NAD</styled-content>+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin</article-title>. <source>Aging Cell</source>, <volume>22</volume>, <elocation-id>e13754</elocation-id>. <pub-id pub-id-type="doi">10.1111/acel.13754</pub-id>
</mixed-citation>
              </p>
              <fn-group id="acel13754-ntgp-0001">
                <fn id="acel13754-note-0001">
                  <p>These authors share senior and corresponding authorship.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="acel13754-body-0001">
            <p>Nicotinamide adenine dinucleotide (oxidized form, NAD<sup>+</sup>) is an essential metabolite involved in a wide range of longevity‐related cellular processes. Classically, NAD<sup>+</sup> functions as a critical coenzyme in cellular metabolism by accepting and shuttling the reducing power generated through metabolic redox reactions to the mitochondria, where NADH is used to generate ATP through oxidative phosphorylation. More recently, NAD<sup>+</sup> has emerged as a critical regulator of NAD<sup>+</sup>‐dependent enzymes that mediate cellular signaling pathways related to metabolism, epigenetic gene regulation, and mitochondrial function, among several other survival‐associated mechanisms (Covarrubias et al., <xref rid="acel13754-bib-0002" ref-type="bibr">2021</xref>). Accordingly, declining NAD<sup>+</sup> concentration in several tissues has emerged as a common pathological factor in various aging‐associated diseases (Katsyuba et al., <xref rid="acel13754-bib-0012" ref-type="bibr">2020</xref>; McReynolds et al., <xref rid="acel13754-bib-0014" ref-type="bibr">2020</xref>).</p>
            <p>The brain is particularly vulnerable to alterations in NAD<sup>+</sup> content during aging due to the high energetic demand of neurons, and brain‐specific decline in NAD+ concentration during aging has been reported in several species, including humans (Mouchiroud et al., <xref rid="acel13754-bib-0015" ref-type="bibr">2013</xref>; Zhu et al., <xref rid="acel13754-bib-0029" ref-type="bibr">2015</xref>). Restoring brain NAD<sup>+</sup> concentration using the dietary NAD<sup>+</sup> precursor nicotinamide riboside (NR) has shown strong efficacy in animal models and has improved key features of neurodegenerative disorders, including amyloid‐beta (Aβ) and tau pathologies (hallmarks of Alzheimer's disease (AD)), neuroinflammation, and mitochondrial dysfunction (Hou et al., <xref rid="acel13754-bib-0011" ref-type="bibr">2021</xref>; Schöndorf et al., <xref rid="acel13754-bib-0019" ref-type="bibr">2018</xref>; Xie et al., <xref rid="acel13754-bib-0024" ref-type="bibr">2019</xref>). Interestingly, brain‐specific insulin resistance is thought to be a major contributor to these neurodegenerative cascades (Mullins et al., <xref rid="acel13754-bib-0016" ref-type="bibr">2017</xref>). NAD<sup>+</sup> supplementation can protect peripheral tissues against insulin resistance (Stromsdorfer et al., <xref rid="acel13754-bib-0020" ref-type="bibr">2016</xref>; Trammell et al., <xref rid="acel13754-bib-0022" ref-type="bibr">2016</xref>; Yoshino et al., <xref rid="acel13754-bib-0027" ref-type="bibr">2021</xref>), although similar effects have yet to be demonstrated for the brain. Overall, augmenting brain‐based NAD<sup>+</sup> metabolism has emerged as a promising strategy for the treatment of neurological disorders (Brakedal et al., <xref rid="acel13754-bib-0001" ref-type="bibr">2022</xref>; Verdin, <xref rid="acel13754-bib-0023" ref-type="bibr">2015</xref>).</p>
            <p>While the preclinical evidence for the use of NR and other NAD<sup>+</sup> precursors in neurological disorders is promising, evidence supporting their ability to augment brain NAD<sup>+</sup> concentration or alter disease biomarkers in humans remains scarce. Furthermore, their capacity to engage insulin signaling pathways in the brain has yet to be explored. Here, we leveraged plasma extracellular vesicles (EVs) enriched for neuronal origin (NEVs) (Mustapic et al., <xref rid="acel13754-bib-0017" ref-type="bibr">2017</xref>) to assess changes in neuronal NAD<sup>+</sup> and NADH concentration, in response to oral supplementation with NR in healthy middle‐aged and older adults. We analyzed plasma samples from 22 healthy older adults (11 M/11F; 65 ± 7 years old) who completed a previously published double‐blind, placebo‐controlled, crossover clinical trial of oral NR (500 mg, 2x/day; 6 weeks), which reported an increase in blood‐cellular NAD<sup>+</sup> concentration and improved cardiovascular parameters following NR administration (Martens et al., <xref rid="acel13754-bib-0013" ref-type="bibr">2018</xref>). Additional details of the clinical trial are provided in the supplemental methods and on <ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link> (NCT02921659). We also measured NEV levels of AD biomarkers Aβ42, p‐Tau‐181, and total Tau due to the strong preclinical evidence demonstrating engagement of these disease‐specific pathways by NAD<sup>+</sup> boosting molecules, such as NR and nicotinamide mononucleotide (NMN). Finally, in an exploratory fashion, we measured phosphoproteins involved in insulin signaling (pSer312‐IRS‐1, pS473‐Akt, pS9‐GSK3‐B, pThr421/Ser424‐p70S6K, pJNK, pERK1/2, and pp38), motivated by the ability of NAD<sup>+</sup> precursors to modulate peripheral insulin resistance (Trammell et al., <xref rid="acel13754-bib-0022" ref-type="bibr">2016</xref>; Yoshino et al., <xref rid="acel13754-bib-0026" ref-type="bibr">2011</xref>). We hypothesized that NR is capable of increasing NAD<sup>+</sup> concentration in NEVs, which we consider a surrogate for a commensurate change in their parental neurons. We also hypothesized that changes in NEV NAD<sup>+</sup> concentration following NR supplementation would be related to changes in biomarkers of AD pathology and insulin signaling.</p>
            <p>NEVs were enriched using an immunoaffinity capture method targeting a sub‐population of plasma EVs that express the neuronal marker L1CAM (described in detail in Mustapic et al. (<xref rid="acel13754-bib-0017" ref-type="bibr">2017</xref>)). To evaluate the quality of our NEV preparations, we assessed canonical‐positive and canonical‐negative EV markers in NEVs, total EVs, and EV‐depleted plasma via immunoblotting according to established guidelines (Thery et al., <xref rid="acel13754-bib-0021" ref-type="bibr">2018</xref>). Our NEV preparations abundantly express the EV markers ALIX and CD9 and are relatively depleted of non‐EV associated cellular debris and plasma lipoproteins, as evidenced by the decreased expression of Golgi marker GM130 and APOA1, respectively (Supporting information Figure <xref rid="acel13754-supitem-0002" ref-type="supplementary-material">S1a</xref>). Nanoparticle tracking analysis (NTA) revealed a size distribution consistent with existing EV literature, with the majority of particles being between 150 and 250 nm. The size distribution and average concentration of NEVs were similar between treatment groups (Supporting information Figure <xref rid="acel13754-supitem-0002" ref-type="supplementary-material">S1b</xref>). NEV concentration was used to normalize protein biomarker values to account for differential NEV recovery, as performed previously (Eitan et al., <xref rid="acel13754-bib-0004" ref-type="bibr">2017</xref>; Eren et al., <xref rid="acel13754-bib-0005" ref-type="bibr">2020</xref>). Lastly, we demonstrate NEV enrichment for neuronal markers L1CAM and β‐III‐tubulin, with 1.6 and 3.7 fold differences between NEVs and total circulating EVs, respectively (Supporting information Figure <xref rid="acel13754-supitem-0002" ref-type="supplementary-material">S1c</xref>).</p>
            <p>We measured NAD<sup>+</sup> and NADH in NEV isolates using a previously developed LC–MS method (Demarest et al., <xref rid="acel13754-bib-0003" ref-type="bibr">2019</xref>). Interestingly, while previously reported to be below quantitation in plasma, our enriched NEVs had NADH levels above quantitation. NAD<sup>+</sup>, however, could be detected but not quantified; therefore, a more sensitive assay was sought (luciferase‐based plate assay, Promega) and quantitative NAD<sup>+</sup> measurements were obtained for 10 of the 22 subjects (five males and five females). As shown in Figure <xref rid="acel13754-fig-0001" ref-type="fig">1a</xref>, NAD<sup>+</sup> levels in NEVs were significantly greater after treatment with NR when compared to placebo (paired <italic toggle="yes">t</italic>test, <italic toggle="yes">p</italic> = 0.0092), while NEV levels of NADH showed no differences (paired <italic toggle="yes">t</italic>test, <italic toggle="yes">p</italic> = 0.215). Consistent with a previous report examining the effects of NR on brain‐specific changes in NAD<sup>+</sup> levels (Brakedal et al., <xref rid="acel13754-bib-0001" ref-type="bibr">2022</xref>), 9/10 subjects with successfully quantified levels showed increased NEV NAD<sup>+</sup> following NR. To address the possibility of heterogeneous treatment effects, we chose to include a responder subgroup (<italic toggle="yes">n</italic> = 9 participants with documented NAD<sup>+</sup> increases; five males and four females) in all subsequent analyses.</p>
            <fig position="float" fig-type="FIGURE" id="acel13754-fig-0001">
              <label>FIGURE 1</label>
              <caption>
                <p>NAD<sup>+</sup> and NADH concentrations in NEVs and change–change correlations with insulin signaling proteins. (a) Concentration of NAD+ after 6 weeks of oral nicotinamide riboside (NR) supplementation was significantly higher in NEVs when compared to placebo (<italic toggle="yes">n</italic> = 10, <italic toggle="yes">p</italic> = 0.0092, paired <italic toggle="yes">t</italic>test), while NADH remained relatively unchanged (<italic toggle="yes">n</italic> = 22, <italic toggle="yes">p</italic> = 0.215, paired <italic toggle="yes">t</italic>test). Bars represent means, and error bars represent SDs. (b) Changes in NAD<sup>+</sup> concentration were positively correlated with changes in pSer473‐Akt, tGSK3β, pGSK3β, tp70S6K, pp70S6K, pERK1/2, and pJNK. Changes in NADH were negatively correlated with changes in pSer473‐Akt, pGSK3β, tp70S6K, pp70S6K, pERK1/2, and pJNK. Numbers inside cells represent Pearson's correlation coefficients; * denotes significance &lt;0.05. Red square depicts analyte selected for visualization in (c). (c) Change to change correlation plots between NAD<sup>+</sup> or NADH and NEV protein biomarkers (<italic toggle="yes">n</italic> = 10).</p>
              </caption>
              <graphic xlink:href="ACEL-22-e13754-g001" position="anchor" id="jats-graphic-3"/>
            </fig>
            <p>The concentration of Aβ42, p‐Tau‐181, and total Tau in NEVs did not change following NR relative to placebo when analyzing all participants; however, we observed a significant decrease in Aβ42 relative to placebo (Figure <xref rid="acel13754-fig-0002" ref-type="fig">2a</xref>, <italic toggle="yes">p</italic> = 0.015) in the responder subgroup. In the entire cohort, we observed no significant changes in pSer‐IRS‐1, pAkt, pGSK3β, or pp70S6K or their total concentrations following NR compared with placebo (Figure <xref rid="acel13754-fig-0002" ref-type="fig">2b</xref>). Moreover, NEV levels of the mitogen‐activated protein kinases pJNK and pp38 were unchanged following NR compared with placebo, while pERK1/2 showed a marginal decrease (Figure <xref rid="acel13754-fig-0002" ref-type="fig">2c</xref>, <italic toggle="yes">p</italic> = 0.066). In the responder subgroup, we observed a significant decrease in pJNK (<italic toggle="yes">p</italic> = 0.036) and pERK1/2 (<italic toggle="yes">p</italic> = 0.038) following NR compared with placebo.</p>
            <fig position="float" fig-type="FIGURE" id="acel13754-fig-0002">
              <label>FIGURE 2</label>
              <caption>
                <p>NEV biomarkers in response to oral nicotinamide riboside supplementation. (a) Alzheimer's disease biomarkers. (b) Canonical insulin/Akt signaling mediators. (c) Alternative MAPK insulin signaling biomarkers. Two‐tailed paired <italic toggle="yes">t</italic>test was used for all analyses; horizontal bars depict mean; error bars depict SEM. * indicates significance &gt;0.05.</p>
              </caption>
              <graphic xlink:href="ACEL-22-e13754-g002" position="anchor" id="jats-graphic-5"/>
            </fig>
            <p>We hypothesized that the effects of NR on NEV protein biomarkers would be, at least in part, linked to changes in NAD<sup>+</sup> levels. Therefore, we explored correlations between changes in NEV NAD<sup>+</sup> and NADH and changes in NEV proteins. Changes in pAkt, tGSK3β, pGSK3β, tp70S6K, pp70S6K, pERK1/2, and pJNK were significantly positively correlated with changes in NAD<sup>+</sup> and negatively correlated with changes in NADH (except for tGSK3β; Figure <xref rid="acel13754-fig-0001" ref-type="fig">1b</xref>). To facilitate the understanding of the directionality of these change–change correlations, we show representative plots for ΔpSer473‐Akt vs. ΔNAD<sup>+</sup> and ΔNADH, Figure <xref rid="acel13754-fig-0001" ref-type="fig">1c</xref>.</p>
            <p>In conclusion, we report the first study examining NEV biomarkers in response to oral NR supplementation. Our primary analysis of NAD<sup>+</sup> and NADH in NEVs suggests an increase in neuronal NAD<sup>+</sup> concentration in response to oral NR supplementation. To gain further mechanistic insights, we performed exploratory analyses, which revealed decreases in NEV concentrations of Aβ42, pJNK, and pERK1/2 following NR compared with placebo, specifically among NAD<sup>+</sup> responders. We hypothesized that NEV‐phosphorylated levels of MAP kinases JNK, ERK1/2, and p38, an alternative branch of the insulin cascade, would be boosted by NR supplementation through enhanced overall insulin signaling in neurons. Instead, our findings suggest that NR may decrease JNK and ERK1/2 phosphorylation. Interestingly, JNK is highly phosphorylated and co‐localizes with Aβ in human post‐mortem AD brain (Zhu et al., <xref rid="acel13754-bib-0028" ref-type="bibr">2001</xref>), and NAD<sup>+</sup> augmentation attenuates both Aβ accumulation and JNK activation in transgenic AD mice (Yao et al., <xref rid="acel13754-bib-0025" ref-type="bibr">2017</xref>). Hyperactivation of ERK1/2 has also been linked to AD (Ferrer et al., <xref rid="acel13754-bib-0009" ref-type="bibr">2006</xref>; Pei et al., <xref rid="acel13754-bib-0018" ref-type="bibr">2002</xref>). Therefore, NR might hold therapeutic value in the context of AD by concomitantly reducing Aβ burden and the activity of JNK and ERK1/2.</p>
            <p>A mechanism by which NR may alter cellular functions is by increasing NAD<sup>+</sup>. To further explore whether changes in NAD+ are mechanistically linked with changes in other NEV biomarkers, we examined change–change correlations between NEV biomarkers following NR relative to placebo. The strong positive correlations between changes in NAD<sup>+</sup> and changes in Akt signaling phosphoproteins, and pERK1/2 and pJNK in NEVs suggest engagement of the insulin signaling cascade (downstream of IRS‐1) in their parent neurons by NR (Figure <xref rid="acel13754-fig-0002" ref-type="fig">2c</xref>). Interestingly, change–change correlations between NADH or NAD<sup>+</sup>, and NEV biomarkers were similar in strength, yet opposite in direction, perhaps, reflecting the redox coupling of these molecules. On the contrary, changes in Aβ42 did not correlate with changes in NAD<sup>+</sup>, suggesting that NR may have pleiotropic effects and that the Aβ42 decrease was mechanistically unrelated. Multiple studies have demonstrated reductions in amyloid pathology following NR treatment in aging and genetically modified mice. NR treatment increases expression of PGC1‐α in the brain, which downregulates the production of Aβ42 by facilitating the degradation of BACE1, which catalyzes the first cleavage in the amyloidogenic processing of APP (Gong et al., <xref rid="acel13754-bib-0010" ref-type="bibr">2013</xref>). The resulting reduced Aβ42 production may be reflected on reduced NEV Aβ42 levels with NR treatment compared with placebo. Furthermore, NR treatment enhances mitophagy and mitochondrial function, which, in turn, promotes the clearance of extracellular amyloid via enhanced phagocytosis by microglia (Fang et al., <xref rid="acel13754-bib-0008" ref-type="bibr">2014</xref>, <xref rid="acel13754-bib-0007" ref-type="bibr">2016</xref>, <xref rid="acel13754-bib-0006" ref-type="bibr">2019</xref>). Thus, NR treatment may engage multiple mechanisms modulating Aβ42 production and clearance even independent of its effects on NAD<sup>+</sup>.</p>
            <p>Our results provide insights into neuronal effects of NR in living humans and highlight the utility of circulating NEVs as a means of demonstrating target engagement in clinical trials. We also show that the utility of NEVs as a source of biomarkers may be expanded beyond proteins to include small molecules, such as NAD<sup>+</sup> and NADH. While we believe our study contains strengths, such as the methodologically robust design of the clinical trial and the breadth of biomarkers measured, we report our findings with caution due to the limited number of subjects and our inability to quantify NAD<sup>+</sup> for the entire cohort.</p>
            <sec id="acel13754-sec-0002">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>C.R.M. and D.R.S. conducted the original clinical trial and provided all the plasma samples for this study. C.R.M. and D.K. conceived the idea for this study and developed the overall study design. M.V., M.M., R.M., K.P., and J.L. isolated the extracellular vesicles from plasma samples and developed and ran all assays to measure NAD<sup>+</sup>/NADH and biomarkers of neurodegenerative disease. M.V., D.K., and C.M. analyzed the data and drafted the manuscript. All authors edited and approved the final manuscript.</p>
            </sec>
            <sec sec-type="COI-statement" id="acel13754-sec-0004">
              <title>CONFLICT OF INTEREST</title>
              <p>The authors declare no competing interests.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="acel13754-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Supinfo S1
</p>
                </caption>
                <media xlink:href="ACEL-22-e13754-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="acel13754-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p><bold>Figure S1</bold> Characterization of neuronal origin‐derived extracellular vesicles (NEVs) isolated from plasma via L1CAM immunoprecipitation. (a) Representative Western blot images and quantification of canonical‐positive (ALIX and CD9) and canonical‐negative (GM130 and APOA1) EV markers in NEVs, total EVs, and EV‐depleted plasma (ordinary one‐way ANOVA, <italic toggle="yes">n</italic> = 3). (b) Treatment group analysis of size distributions, mean size, mean concentration, and mode size of NEV isolates as determined by nanoparticle tracking analysis. Vertical lines depict SD. (c) Western blot images and quantification of neuronal marker β‐III‐tubulin, immunoprecipitation target L1CAM, and EV marker CD9 in NEVs, total EVs, and EV‐depleted plasma. Human brain lysate was used as a positive control for neuronal proteins (unpaired <italic toggle="yes">t</italic>test, <italic toggle="yes">n</italic> = 3). Images analyzed using FIJI/Image J. CD9 used as loading control; error bars depict SD; *indicates significance &lt;0.05; **indicates significance &lt;0.005.</p>
                  <p><bold>FIGURE S2</bold> Calibration curve used to interpolate NAD+ concentrations from Promega NAD+/NADH luciferase assay. NAD+ Standards were created at concentrations of 10 nM, 5 nM, 2.5 nM, 1.25 nM, and 0.625 nM.</p>
                  <p><bold>FIGURE S3</bold> NADH levels in L1CAM+ EVs in responders only. Even when analyzing responders (defined as subjects with documented NAD+ increases in L1CAM+ EVs) only (<italic toggle="yes">n</italic> = 9), levels of NADH in plasma extracellular vesicles enriched for neuronal origin remain relatively unchanged after oral NR supplementation when compared to the placebo condition (two‐tailed paired <italic toggle="yes">t</italic>test, <italic toggle="yes">p</italic> = 0.44).</p>
                </caption>
                <media xlink:href="ACEL-22-e13754-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="acel13754-sec-0003">
              <title>ACKNOWLEDGMENTS</title>
              <p>This work was supported in part by NIH grant K01 AG054731 and in part by the Intramural Program of the National Institute on Aging, NIH. The original clinical trial for which the samples in this study were derived was registered on <ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link> under the identifier NCT02921659 and was supported by NIH grants T32 AG000279 and UL1 TR001082 and a fellowship from the Glenn Foundation and American Federation of Aging Research. NR and placebo capsules for the original clinical trial were provided by ChromaDex, Inc.</p>
            </ack>
            <sec sec-type="data-availability" id="acel13754-sec-0006">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
            </sec>
            <ref-list content-type="cited-references" id="acel13754-bibl-0001">
              <title>REFERENCES</title>
              <ref id="acel13754-bib-0001">
                <mixed-citation publication-type="journal" id="acel13754-cit-0001"><string-name><surname>Brakedal</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Dölle</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Riemer</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Nido</surname>, <given-names>G. S.</given-names></string-name>, <string-name><surname>Skeie</surname>, <given-names>G. O.</given-names></string-name>, <string-name><surname>Craven</surname>, <given-names>A. R.</given-names></string-name>, <string-name><surname>Schwarzlmüller</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Brekke</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Diab</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sverkeli</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Skjeie</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Varhaug</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Tysnes</surname>, <given-names>O.‐B.</given-names></string-name>, <string-name><surname>Peng</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Haugarvoll</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ziegler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Grüner</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Eidelberg</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Tzoulis</surname>, <given-names>C.</given-names></string-name> (<year>2022</year>). <article-title>The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease</article-title>. <source>Cell Metabolism</source>, <volume>34</volume>(<issue>3</issue>), <fpage>396</fpage>–<lpage>407.e396</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2022.02.001</pub-id>
<pub-id pub-id-type="pmid">35235774</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0002">
                <mixed-citation publication-type="journal" id="acel13754-cit-0002"><string-name><surname>Covarrubias</surname>, <given-names>A. J.</given-names></string-name>, <string-name><surname>Perrone</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Grozio</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Verdin</surname>, <given-names>E.</given-names></string-name> (<year>2021</year>). <article-title>NAD+ metabolism and its roles in cellular processes during ageing</article-title>. <source>Nature Reviews Molecular Cell Biology</source>, <volume>22</volume>(<issue>2</issue>), <fpage>119</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-00313-x</pub-id>
<pub-id pub-id-type="pmid">33353981</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0003">
                <mixed-citation publication-type="journal" id="acel13754-cit-0003"><string-name><surname>Demarest</surname>, <given-names>T. G.</given-names></string-name>, <string-name><surname>Truong</surname>, <given-names>G. T. D.</given-names></string-name>, <string-name><surname>Lovett</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mohanty</surname>, <given-names>J. G.</given-names></string-name>, <string-name><surname>Mattison</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Mattson</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Ferrucci</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Bohr</surname>, <given-names>V. A.</given-names></string-name>, &amp; <string-name><surname>Moaddel</surname>, <given-names>R.</given-names></string-name> (<year>2019</year>). <article-title>Assessment of NAD+ metabolism in human cell cultures, erythrocytes, cerebrospinal fluid and primate skeletal muscle</article-title>. <source>Analytical Biochemistry</source>, <volume>572</volume>, <fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2019.02.019</pub-id>
<pub-id pub-id-type="pmid">30822397</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0004">
                <mixed-citation publication-type="journal" id="acel13754-cit-0004"><string-name><surname>Eitan</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Tosti</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Suire</surname>, <given-names>C. N.</given-names></string-name>, <string-name><surname>Cava</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Berkowitz</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bertozzi</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Raefsky</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Veronese</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Spangler</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Spelta</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Mustapic</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kapogiannis</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Mattson</surname>, <given-names>M. P.</given-names></string-name>, &amp; <string-name><surname>Fontana</surname>, <given-names>L.</given-names></string-name> (<year>2017</year>). <article-title>In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles</article-title>. <source>Aging Cell</source>, <volume>16</volume>(<issue>6</issue>), <fpage>1430</fpage>–<lpage>1433</lpage>. <pub-id pub-id-type="doi">10.1111/acel.12657</pub-id>
<pub-id pub-id-type="pmid">28921841</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0005">
                <mixed-citation publication-type="journal" id="acel13754-cit-0005"><string-name><surname>Eren</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Hunt</surname>, <given-names>J. F. V.</given-names></string-name>, <string-name><surname>Shardell</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chawla</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tran</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Vogt</surname>, <given-names>N. M.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>S. C.</given-names></string-name>, <string-name><surname>Bendlin</surname>, <given-names>B. B.</given-names></string-name>, &amp; <string-name><surname>Kapogiannis</surname>, <given-names>D.</given-names></string-name> (<year>2020</year>). <article-title>Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle age</article-title>. <source>Alzheimer's Dement</source>, <volume>16</volume>(<issue>9</issue>), <fpage>1293</fpage>–<lpage>1304</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12130</pub-id>
<pub-id pub-id-type="pmid">32588967</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0006">
                <mixed-citation publication-type="journal" id="acel13754-cit-0006"><string-name><surname>Fang</surname>, <given-names>E. F.</given-names></string-name>, <string-name><surname>Hou</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Palikaras</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Adriaanse</surname>, <given-names>B. A.</given-names></string-name>, <string-name><surname>Kerr</surname>, <given-names>J. S.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Lautrup</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hasan‐Olive</surname>, <given-names>M. M.</given-names></string-name>, <string-name><surname>Caponio</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Dan</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Rocktäschel</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Croteau</surname>, <given-names>D. L.</given-names></string-name>, <string-name><surname>Akbari</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Greig</surname>, <given-names>N. H.</given-names></string-name>, <string-name><surname>Fladby</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nilsen</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Cader</surname>, <given-names>M. Z.</given-names></string-name>, <string-name><surname>Mattson</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Tavernarakis</surname>, <given-names>N.</given-names></string-name>, &amp; <string-name><surname>Bohr</surname>, <given-names>V. A.</given-names></string-name> (<year>2019</year>). <article-title>Mitophagy inhibits amyloid‐β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease</article-title>. <source>Nature Neuroscience</source>, <volume>22</volume>(<issue>3</issue>), <fpage>401</fpage>–<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-018-0332-9</pub-id>
<pub-id pub-id-type="pmid">30742114</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0007">
                <mixed-citation publication-type="journal" id="acel13754-cit-0007"><string-name><surname>Fang</surname>, <given-names>E. F.</given-names></string-name>, <string-name><surname>Kassahun</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Croteau</surname>, <given-names>D. L.</given-names></string-name>, <string-name><surname>Scheibye‐Knudsen</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Marosi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Shamanna</surname>, <given-names>R. A.</given-names></string-name>, <string-name><surname>Kalyanasundaram</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bollineni</surname>, <given-names>R. C.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Iser</surname>, <given-names>W. B.</given-names></string-name>, <string-name><surname>Wollman</surname>, <given-names>B. N.</given-names></string-name>, <string-name><surname>Morevati</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kerr</surname>, <given-names>J. S.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Waltz</surname>, <given-names>T. B.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sinclair</surname>, <given-names>D. A.</given-names></string-name>, … <string-name><surname>Bohr</surname>, <given-names>V. A.</given-names></string-name> (<year>2016</year>). <article-title>NAD+ replenishment improves lifespan and Healthspan in ataxia telangiectasia models via mitophagy and DNA repair</article-title>. <source>Cell Metabolism</source>, <volume>24</volume>(<issue>4</issue>), <fpage>566</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.004</pub-id>
<pub-id pub-id-type="pmid">27732836</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0008">
                <mixed-citation publication-type="journal" id="acel13754-cit-0008"><string-name><surname>Fang</surname>, <given-names>E. F.</given-names></string-name>, <string-name><surname>Scheibye‐Knudsen</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Brace</surname>, <given-names>L. E.</given-names></string-name>, <string-name><surname>Kassahun</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>SenGupta</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nilsen</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Mitchell</surname>, <given-names>J. R.</given-names></string-name>, <string-name><surname>Croteau</surname>, <given-names>D. L.</given-names></string-name>, &amp; <string-name><surname>Bohr</surname>, <given-names>V. A.</given-names></string-name> (<year>2014</year>). <article-title>Defective mitophagy in XPA via PARP‐1 hyperactivation and NAD(+)/SIRT1 reduction</article-title>. <source>Cell</source>, <volume>157</volume>(<issue>4</issue>), <fpage>882</fpage>–<lpage>896</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.03.026</pub-id>
<pub-id pub-id-type="pmid">24813611</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0009">
                <mixed-citation publication-type="journal" id="acel13754-cit-0009"><string-name><surname>Ferrer</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Blanco</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Carmona</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ribera</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Goutan</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Puig</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Rey</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>Cardozo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Viñals</surname>, <given-names>F.</given-names></string-name>, &amp; <string-name><surname>Ribalta</surname>, <given-names>T.</given-names></string-name> (<year>2006</year>). <article-title>Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in Neurons and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration</article-title>. <source>Brain Pathology</source>, <volume>11</volume>(<issue>2</issue>), <fpage>144</fpage>–<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.2001.tb00387.x</pub-id>
</mixed-citation>
              </ref>
              <ref id="acel13754-bib-0010">
                <mixed-citation publication-type="journal" id="acel13754-cit-0010"><string-name><surname>Gong</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Pan</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Vempati</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Knable</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ho</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sastre</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ono</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Sauve</surname>, <given-names>A. A.</given-names></string-name>, &amp; <string-name><surname>Pasinetti</surname>, <given-names>G. M.</given-names></string-name> (<year>2013</year>). <article-title>Nicotinamide riboside restores cognition through an upregulation of proliferator‐activated receptor‐γ coactivator 1α regulated β‐secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models</article-title>. <source>Neurobiology of Aging</source>, <volume>34</volume>(<issue>6</issue>), <fpage>1581</fpage>–<lpage>1588</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.12.005</pub-id>
<pub-id pub-id-type="pmid">23312803</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0011">
                <mixed-citation publication-type="journal" id="acel13754-cit-0011"><string-name><surname>Hou</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lautrup</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Cordonnier</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mattson</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Croteau</surname>, <given-names>D. L.</given-names></string-name>, &amp; <string-name><surname>Bohr</surname>, <given-names>V. A.</given-names></string-name> (<year>2021</year>). <article-title>NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS‐STING</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>118</volume>(<issue>37</issue>), <fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2011226118</pub-id>
</mixed-citation>
              </ref>
              <ref id="acel13754-bib-0012">
                <mixed-citation publication-type="journal" id="acel13754-cit-0012"><string-name><surname>Katsyuba</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Romani</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hofer</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Auwerx</surname>, <given-names>J.</given-names></string-name> (<year>2020</year>). <article-title>NAD+ homeostasis in health and disease</article-title>. <source>Nature Metabolism</source>, <volume>2</volume>(<issue>1</issue>), <fpage>9</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/s42255-019-0161-5</pub-id>
</mixed-citation>
              </ref>
              <ref id="acel13754-bib-0013">
                <mixed-citation publication-type="journal" id="acel13754-cit-0013"><string-name><surname>Martens</surname>, <given-names>C. R.</given-names></string-name>, <string-name><surname>Denman</surname>, <given-names>B. A.</given-names></string-name>, <string-name><surname>Mazzo</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Armstrong</surname>, <given-names>M. L.</given-names></string-name>, <string-name><surname>Reisdorph</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>McQueen</surname>, <given-names>M. B.</given-names></string-name>, <string-name><surname>Chonchol</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Seals</surname>, <given-names>D. R.</given-names></string-name> (<year>2018</year>). <article-title>Chronic nicotinamide riboside supplementation is well‐tolerated and elevates NAD+ in healthy middle‐aged and older adults</article-title>. <source>Nature Communications</source>, <volume>9</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-03421-7</pub-id>
</mixed-citation>
              </ref>
              <ref id="acel13754-bib-0014">
                <mixed-citation publication-type="journal" id="acel13754-cit-0014"><string-name><surname>McReynolds</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Chellappa</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Baur</surname>, <given-names>J. A.</given-names></string-name> (<year>2020</year>). <article-title>Age‐related NAD(+) decline</article-title>. <source>Experimental Gerontology</source>, <volume>134</volume>, <elocation-id>110888</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.exger.2020.110888</pub-id>
<pub-id pub-id-type="pmid">32097708</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0015">
                <mixed-citation publication-type="journal" id="acel13754-cit-0015"><string-name><surname>Mouchiroud</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Houtkooper</surname>, <given-names>R. H.</given-names></string-name>, <string-name><surname>Moullan</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Katsyuba</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Ryu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Canto</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Mottis</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Jo</surname>, <given-names>Y.‐S.</given-names></string-name>, <string-name><surname>Viswanathan</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Schoonjans</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Guarente</surname>, <given-names>L.</given-names></string-name>, &amp; <string-name><surname>Auwerx</surname>, <given-names>J.</given-names></string-name> (<year>2013</year>). <article-title>The NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling</article-title>. <source>Cell</source>, <volume>154</volume>(<issue>2</issue>), <fpage>430</fpage>–<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.06.016</pub-id>
<pub-id pub-id-type="pmid">23870130</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0016">
                <mixed-citation publication-type="journal" id="acel13754-cit-0016"><string-name><surname>Mullins</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Diehl</surname>, <given-names>T. C.</given-names></string-name>, <string-name><surname>Chia</surname>, <given-names>C. W.</given-names></string-name>, &amp; <string-name><surname>Kapogiannis</surname>, <given-names>D.</given-names></string-name> (<year>2017</year>). <article-title>Insulin resistance as a link between amyloid‐Beta and tau pathologies in Alzheimer's disease</article-title>. <source>Frontiers in Aging Neuroscience</source>, <volume>9</volume>, <elocation-id>118</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnagi.2017.00118</pub-id>
<pub-id pub-id-type="pmid">28515688</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0017">
                <mixed-citation publication-type="journal" id="acel13754-cit-0017"><string-name><surname>Mustapic</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Eitan</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Werner</surname>, <given-names>J. K.</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Berkowitz</surname>, <given-names>S. T.</given-names></string-name>, <string-name><surname>Lazaropoulos</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Tran</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Goetzl</surname>, <given-names>E. J.</given-names></string-name>, &amp; <string-name><surname>Kapogiannis</surname>, <given-names>D.</given-names></string-name> (<year>2017</year>). <article-title>Plasma extracellular vesicles enriched for neuronal origin: A potential window into brain pathologic processes</article-title>. <source>Frontiers in Neuroscience</source>, <volume>11</volume>, <elocation-id>278</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnins.2017.00278</pub-id>
<pub-id pub-id-type="pmid">28588440</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0018">
                <mixed-citation publication-type="journal" id="acel13754-cit-0018"><string-name><surname>Pei</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Braak</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>An</surname>, <given-names>W. L.</given-names></string-name>, <string-name><surname>Winblad</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Cowburn</surname>, <given-names>R. F.</given-names></string-name>, <string-name><surname>Iqbal</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Grundke‐Iqbal</surname>, <given-names>I.</given-names></string-name> (<year>2002</year>). <article-title>Up‐regulation of mitogen‐activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease</article-title>. <source>Molecular Brain Research</source>, <volume>109</volume>(<issue>1–2</issue>), <fpage>45</fpage>–<lpage>55</lpage>. Pii S0169‐328x(02)00488‐6. <pub-id pub-id-type="doi">10.1016/S0169-328x(02)00488-6</pub-id>
<pub-id pub-id-type="pmid">12531514</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0019">
                <mixed-citation publication-type="journal" id="acel13754-cit-0019"><string-name><surname>Schöndorf</surname>, <given-names>D. C.</given-names></string-name>, <string-name><surname>Ivanyuk</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Baden</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Sanchez‐Martinez</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>De Cicco</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Giunta</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Schwarz</surname>, <given-names>L. K.</given-names></string-name>, <string-name><surname>Di Napoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Panagiotakopoulou</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Nestel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Keatinge</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Pruszak</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bandmann</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Heimrich</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Gasser</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Whitworth</surname>, <given-names>A. J.</given-names></string-name>, &amp; <string-name><surname>Deleidi</surname>, <given-names>M.</given-names></string-name> (<year>2018</year>). <article-title>The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and Fly models of Parkinson's disease</article-title>. <source>Cell Reports</source>, <volume>23</volume>(<issue>10</issue>), <fpage>2976</fpage>–<lpage>2988</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.009</pub-id>
<pub-id pub-id-type="pmid">29874584</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0020">
                <mixed-citation publication-type="journal" id="acel13754-cit-0020"><string-name><surname>Stromsdorfer</surname>, <given-names>K. L.</given-names></string-name>, <string-name><surname>Yamaguchi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yoon</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>Moseley</surname>, <given-names>A. C.</given-names></string-name>, <string-name><surname>Franczyk</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Kelly</surname>, <given-names>S. C.</given-names></string-name>, <string-name><surname>Qi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Imai</surname>, <given-names>S.‐I.</given-names></string-name>, &amp; <string-name><surname>Yoshino</surname>, <given-names>J.</given-names></string-name> (<year>2016</year>). <article-title>NAMPT‐mediated NAD + biosynthesis in adipocytes regulates adipose tissue function and multi‐organ insulin sensitivity in mice</article-title>. <source>Cell Reports</source>, <volume>16</volume>(<issue>7</issue>), <fpage>1851</fpage>–<lpage>1860</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.07.027</pub-id>
<pub-id pub-id-type="pmid">27498863</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0021">
                <mixed-citation publication-type="journal" id="acel13754-cit-0021"><string-name><surname>Thery</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Witwer</surname>, <given-names>K. W.</given-names></string-name>, <string-name><surname>Aikawa</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Alcaraz</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>Anderson</surname>, <given-names>J. D.</given-names></string-name>, <string-name><surname>Andriantsitohaina</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Antoniou</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Arab</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Archer</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Atkin‐Smith</surname>, <given-names>G. K.</given-names></string-name>, <string-name><surname>Ayre</surname>, <given-names>D. C.</given-names></string-name>, <string-name><surname>Bach</surname>, <given-names>J.‐M.</given-names></string-name>, <string-name><surname>Bachurski</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Baharvand</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Balaj</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Baldacchino</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bauer</surname>, <given-names>N. N.</given-names></string-name>, <string-name><surname>Baxter</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Bebawy</surname>, <given-names>M.</given-names></string-name>, … <string-name><surname>Zuba‐Surma</surname>, <given-names>E. K.</given-names></string-name> (<year>2018</year>). <article-title>Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines</article-title>. <source>Journal of Extracellular Vesicles</source>, <volume>7</volume>(<issue>1</issue>), <elocation-id>1535750</elocation-id>. <pub-id pub-id-type="doi">10.1080/20013078.2018.1535750</pub-id>
<pub-id pub-id-type="pmid">30637094</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0022">
                <mixed-citation publication-type="journal" id="acel13754-cit-0022"><string-name><surname>Trammell</surname>, <given-names>S. A. J.</given-names></string-name>, <string-name><surname>Weidemann</surname>, <given-names>B. J.</given-names></string-name>, <string-name><surname>Chadda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Yorek</surname>, <given-names>M. S.</given-names></string-name>, <string-name><surname>Holmes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Coppey</surname>, <given-names>L. J.</given-names></string-name>, <string-name><surname>Obrosov</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kardon</surname>, <given-names>R. H.</given-names></string-name>, <string-name><surname>Yorek</surname>, <given-names>M. A.</given-names></string-name>, &amp; <string-name><surname>Brenner</surname>, <given-names>C.</given-names></string-name> (<year>2016</year>). <article-title>Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice</article-title>. <source>Scientific Reports</source>, <volume>6</volume>(<issue>1</issue>), <elocation-id>26933</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep26933</pub-id>
<pub-id pub-id-type="pmid">27230286</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0023">
                <mixed-citation publication-type="journal" id="acel13754-cit-0023"><string-name><surname>Verdin</surname>, <given-names>E.</given-names></string-name> (<year>2015</year>). <article-title>NAD<sup>+</sup> in aging, metabolism, and neurodegeneration</article-title>. <source>Science (New York, N.Y.)</source>, <volume>350</volume>(<issue>6265</issue>), <fpage>1208</fpage>–<lpage>1213</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac4854</pub-id>
<pub-id pub-id-type="pmid">26785480</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0024">
                <mixed-citation publication-type="journal" id="acel13754-cit-0024"><string-name><surname>Xie</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>T. F.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>Y. B.</given-names></string-name>, &amp; <string-name><surname>Zhang</surname>, <given-names>W. P.</given-names></string-name> (<year>2019</year>). <article-title>Nicotinamide ribose ameliorates cognitive impairment of aged and Alzheimer's disease model mice</article-title>. <source>Metabolic Brain Disease</source>, <volume>34</volume>(<issue>1</issue>), <fpage>353</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1007/s11011-018-0346-8</pub-id>
<pub-id pub-id-type="pmid">30523581</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0025">
                <mixed-citation publication-type="journal" id="acel13754-cit-0025"><string-name><surname>Yao</surname>, <given-names>Z. W.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>W. H.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>Z. G.</given-names></string-name>, &amp; <string-name><surname>Jia</surname>, <given-names>P.</given-names></string-name> (<year>2017</year>). <article-title>Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease</article-title>. <source>Neuroscience Letters</source>, <volume>647</volume>, <fpage>133</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2017.03.027</pub-id>
<pub-id pub-id-type="pmid">28330719</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0026">
                <mixed-citation publication-type="journal" id="acel13754-cit-0026"><string-name><surname>Yoshino</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kathryn</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Imai</surname>, <given-names>S.‐I.</given-names></string-name> (<year>2011</year>). <article-title>Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet‐ and age‐induced diabetes in mice</article-title>. <source>Cell Metabolism</source>, <volume>14</volume>(<issue>4</issue>), <fpage>528</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2011.08.014</pub-id>
<pub-id pub-id-type="pmid">21982712</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0027">
                <mixed-citation publication-type="journal" id="acel13754-cit-0027"><string-name><surname>Yoshino</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Yoshino</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kayser</surname>, <given-names>B. D.</given-names></string-name>, <string-name><surname>Patti</surname>, <given-names>G. J.</given-names></string-name>, <string-name><surname>Franczyk</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Mills</surname>, <given-names>K. F.</given-names></string-name>, <string-name><surname>Sindelar</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Pietka</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Patterson</surname>, <given-names>B. W.</given-names></string-name>, <string-name><surname>Imai</surname>, <given-names>S.‐I.</given-names></string-name>, &amp; <string-name><surname>Klein</surname>, <given-names>S.</given-names></string-name> (<year>2021</year>). <article-title>Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women</article-title>. <source>Science</source>, <volume>372</volume>(<issue>6547</issue>), <fpage>1224</fpage>–<lpage>1229</lpage>. <pub-id pub-id-type="doi">10.1126/science.abe9985</pub-id>
<pub-id pub-id-type="pmid">33888596</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0028">
                <mixed-citation publication-type="journal" id="acel13754-cit-0028"><string-name><surname>Zhu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Raina</surname>, <given-names>A. K.</given-names></string-name>, <string-name><surname>Rottkamp</surname>, <given-names>C. A.</given-names></string-name>, <string-name><surname>Aliev</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Perry</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Boux</surname>, <given-names>H.</given-names></string-name>, &amp; <string-name><surname>Smith</surname>, <given-names>M. A.</given-names></string-name> (<year>2001</year>). <article-title>Activation and redistribution of c‐Jun N‐terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease</article-title>. <source>Journal of Neurochemistry</source>, <volume>76</volume>(<issue>2</issue>), <fpage>435</fpage>–<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00046.x</pub-id>
<pub-id pub-id-type="pmid">11208906</pub-id></mixed-citation>
              </ref>
              <ref id="acel13754-bib-0029">
                <mixed-citation publication-type="journal" id="acel13754-cit-0029"><string-name><surname>Zhu</surname>, <given-names>X. H.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>B. Y.</given-names></string-name>, <string-name><surname>Ugurbil</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Chen</surname>, <given-names>W.</given-names></string-name> (<year>2015</year>). <article-title>In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>112</volume>(<issue>9</issue>), <fpage>2876</fpage>–<lpage>2881</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1417921112</pub-id>
<pub-id pub-id-type="pmid">25730862</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
